• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.

作者信息

Moritake Hiroshi, Tanaka Shiro, Nakayama Hideki, Miyamura Takako, Iwamoto Shotaro, Shimada Akira, Terui Kiminori, Saito Akiko, Shiba Norio, Hayashi Yasuhide, Tomizawa Daisuke, Taga Takashi, Goto Hiroaki, Hasegawa Daisuke, Horibe Keizo, Mizutani Shuki, Adachi Souichi

机构信息

Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Clinical Research Center, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan.

出版信息

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26491. Epub 2017 Feb 24.

DOI:10.1002/pbc.26491
PMID:28233452
Abstract
摘要

相似文献

1
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.儿童复发性核心结合因子急性髓系白血病的转归：来自日本儿童白血病/淋巴瘤研究组（JPLSG）AML-05R研究的结果
Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26491. Epub 2017 Feb 24.
2
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.儿童复发急性髓系白血病的结局：来自日本儿科白血病/淋巴瘤研究组 AML-05R 研究的结果。
Pediatr Blood Cancer. 2021 Jan;68(1):e28736. doi: 10.1002/pbc.28736. Epub 2020 Sep 29.
3
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星用于复发性儿童急性髓系白血病
Pediatr Int. 2017 Oct;59(10):1046-1052. doi: 10.1111/ped.13378.
4
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.常用挽救性化疗方案对难治性或复发性急性髓系白血病患者的疗效：一项回顾性队列研究。
Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102.
5
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).尝试优化无核心结合因子的儿童急性髓细胞白血病的诱导后治疗：来自日本儿科白血病/淋巴瘤研究组（JPLSG）的报告。
Pediatr Blood Cancer. 2020 Dec;67(12):e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4.
6
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星（FLAG-IDA）治疗预后不良的儿童急性白血病：哈杰泰佩大学的经验
Pediatr Hematol Oncol. 2010 Oct;27(7):517-28. doi: 10.3109/08880018.2010.493578.
7
Salvaging AML with CLAG: novel option, or more of the same?使用CLAG挽救急性髓系白血病：新选择，还是老一套？
Leuk Res. 2011 Mar;35(3):297-8. doi: 10.1016/j.leukres.2010.10.015. Epub 2010 Nov 11.
8
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.氟达拉滨、阿糖胞苷和粒细胞集落刺激因子（FLAG）化疗方案是一种替代基于蒽环类药物的疗法，用于治疗已有心脏病的急性髓性白血病患者。
Eur J Haematol. 2016 Nov;97(5):471-478. doi: 10.1111/ejh.12757. Epub 2016 May 3.
9
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.氟达拉滨与阿糖胞苷联合用于诱导成年急性髓系白血病患者治疗
Acta Haematol. 2017;137(1):15-16. doi: 10.1159/000449277. Epub 2016 Nov 3.
10
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.氟达拉滨、大剂量阿糖胞苷和粒细胞集落刺激因子（FLAG）方案用于儿童难治性及高危复发性急性白血病
Med Pediatr Oncol. 1999 Jun;32(6):411-5. doi: 10.1002/(sici)1096-911x(199906)32:6<411::aid-mpo3>3.0.co;2-k.

引用本文的文献

1
Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).CBF 儿科 AML 伴 t(8;21)患者的预后因素和结果与 inv(16)患者不同。
BMC Cancer. 2023 May 25;23(1):476. doi: 10.1186/s12885-023-10965-5.
2
Natural HDAC-1/8 inhibitor baicalein exerts therapeutic effect in CBF-AML.天然HDAC-1/8抑制剂黄芩素对核心结合因子急性髓系白血病具有治疗作用。
Clin Transl Med. 2020 Aug;10(4):e154. doi: 10.1002/ctm2.154.